Copyright
©2013 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Gastroenterol. Oct 21, 2013; 19(39): 6515-6522
Published online Oct 21, 2013. doi: 10.3748/wjg.v19.i39.6515
Published online Oct 21, 2013. doi: 10.3748/wjg.v19.i39.6515
Risk prediction of hepatitis B virus-related hepatocellular carcinoma in the era of antiviral therapy
Grace Lai-Hung Wong, Vincent Wai-Sun Wong, Institute of Digestive Disease and Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, China
Author contributions: Wong GLH and Wong VWS designed and performed the research, analyzed the data and wrote the paper.
Correspondence to: Vincent WS Wong, MD, Institute of Digestive Disease and Department of Medicine and Therapeutics, The Chinese University of Hong Kong, 9/F Prince of Wales Hospital, 30-32 Ngan Shing Street, Shatin, Hong Kong, China. wongv@cuhk.edu.hk
Telephone: +86-852-26323173 Fax: +86-852-26373852
Received: July 8, 2013
Revised: August 19, 2013
Accepted: September 4, 2013
Published online: October 21, 2013
Revised: August 19, 2013
Accepted: September 4, 2013
Published online: October 21, 2013
Core Tip
Core tip: CU-hepatocellular carcinoma (HCC), GAG-HCC and REACH-B scores accurately predict subsequent HCC development in both treatment-naïve patients with chronic hepatitis B and those receiving antiviral therapy. At the recommended cutoff values, baseline CU-HCC and REACH-B scores had high sensitivity, while the GAG-HCC score had high specificity in predicting HCC. Patients persistently in the low-risk category have the lowest risk of HCC; those “downgraded” in risk category have significantly lower, but a small risk of HCC compared to those in the high-risk category. Patients in the high-risk category either at baseline or after treatment should undergo HCC surveillance.